A Phase III, comparative study of KRP-AM1977Y in community- acquired pneumonia

A Phase III, randomized double-blind comparative study of KRP-AM1977Y for patients with community acquired pneumonia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223246

Enrollment

280

Registered

2016-06-21

Start date

2016-07-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community acquired pneumonia (including Mycoplasma pneumonia, Chlamydia Pneumonia, or Legionella pneumonia)

Interventions

investigational material(s) Generic name etc : KRP-AM1977Y 150mg KIT FOR INTRAVENOUS DRIP INFUSION INN of investigational material : - Therapeutic category code : 624 Synthetic antibacterials Dosage a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Community acquired pneumonia with clear infection symptoms

Exclusion criteria

Exclusion criteria: Pneumonia patient except the community-acquired pneumonia Patient with serious functional disorder that would unsuitable for the study Patient showing the tendency to improve pneumonia symptoms by other agents etc.

Design outcomes

Primary

Measure	Time frame
efficacy Clinical efficacy at test of cure Assessment of clinical response by comparing the clinical findings and chest X-ray or CT results.	—

Secondary

Measure	Time frame
efficacy Clinical efficacy at end of treatment, etc. Assessment of clinical response by comparing the clinical findings and chest X-ray or CT results.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026